Mr. Wilson is an experienced intellectual property attorney with deep expertise in drug development WALTHAM, Mass. – Dyne Therapeutics, a biotechnology company pioneering life-transforming therapies for patients with serious muscle diseases, today announced the appointment of Daniel Wilson as vice president, head of intellectual property. Mr. Wilson comes to Dyne from Celgene, where he served as senior corporate counsel. He is an accomplished intellectual property attorney with extensive experience leading and executing IP strategy in the biotechnology industry. Dyne has built a strong IP position to support its FORCETM platform, which uses highly targeted antibodies to deliver disease-modifying therapeutics directly to skeletal, cardiac and smooth muscle tissue. In his new role, Mr. Wilson will focus on bolstering and expanding Dyne’s IP position across multiple programs. “Dyne has developed a truly novel and very exciting approach to treating progressive muscle diseases,” said Mr. Wilson. “The team’s recent data presentation underscores the power of the proprietary FORCE platform to deliver durable, functional benefits even at low doses – and to deliver modern oligonucleotide therapeutics for muscle diseases. I’m thrilled to come on board to support and advance Dyne’s intellectual property strategy at this important moment in the company’s development.” Dan’s impressive background in intellectual property law and deep experience in drug development will be a valuable asset to Dyne as we continue to enhance our robust IP position and build the leading muscle disease company,” said Joshua Brumm, president and chief executive officer of Dyne. “We look forward to the significant contributions Dan will bring as we advance the development of transformative, highly targeted therapies for myotonic dystrophy, Duchenne muscular dystrophy and other disorders.” At Celgene, Mr. Wilson led the intellectual property group for Celgene’s Massachusetts office while working on a variety of global business deals, collaborations and product development teams. During his time at Celgene, Mr. Wilson served as patent counsel for the project teams that launched two new medicines. Prior to working at Celgene, Mr. Wilson was intellectual property counsel at Sunovion Pharmaceuticals. He began his legal career working at the law firms of Goodwin Procter and Testa, Hurwitz & Thibeault, where he worked with a variety of life science companies. Mr. Wilson received his B.A. in biology from Swarthmore College, his M.S. in pharmacology from University of Pennsylvania and his J.D. from Boston University School of Law. About Dyne Therapeutics Dyne Therapeutics is pioneering life-transforming therapies for patients with serious muscle diseases. The company’s FORCETM platform delivers oligonucleotides and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision to restore muscle health. Dyne is advancing treatments for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Dyne was founded by Atlas Venture and is headquartered in Waltham, Mass. For more information, please visit www.dyne-tx.com, and follow us on TwitterLinkedIn and Facebook. Media Contact Ten Bridge Communications Stephanie Simon, (617) 581-9333 stephanie@tenbridgecommunications.com Dyne to evaluate therapies targeting genetic cause of FSHD under agreement with international research organization UMONS Leading FSHD researcher Jeffrey Statland, M.D., appointed to Scientific Advisory Board  WALTHAM, Mass. – Dyne Therapeutics, a biotechnology company pioneering life-transforming therapies for patients with serious muscle diseases, today announced the acceleration of its programs in facioscapulohumeral muscular dystrophy (FSHD) through the exclusive licensing of technologies to target the disease, as well as the appointment of leading researcher Jeffrey Statland, M.D., to its Scientific Advisory Board. Dr. Statland is an associate professor of neurology in the Department of Neurology at the University of Kansas Medical Center. He is also the co-principal investigator for ReSolve (Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD), an ongoing observational study run by the FSHD Clinical Trial Research Network (CTRN) and supported by Dyne Therapeutics. The intellectual property exclusively licensed by Dyne targets the gene DUX4, which is the genetic basis of FSHD, and was developed by Professor Alexandra Belayew and Dr. Frédérique Coppée at the University of Mons (UMONS) Molecular Biology Laboratory in Belgium. Dyne is advancing an FSHD program using this suite of DUX4-targeting technology in combination with its proprietary FORCETM platform. FSHD is a rare, debilitating muscle disease for which there are no approved treatments. Dyne’s proprietary FORCE platform enables targeted delivery of a therapeutic inside the muscle cells of FSHD patients, where it is expected to reduce aberrant expression of the DUX4 protein and halt the loss of muscle function that characterizes FSHD. People affected by FSHD experience muscle pain and progressive skeletal muscle loss throughout the body that significantly affects their strength, mobility and quality of life. The muscle weakness often starts in the face, making it difficult to smile, and may progress to the point where affected individuals become dependent upon the use of a wheelchair for mobility. “Dyne has made a commitment to alleviating the FSHD burden for affected individuals and families. Today’s announcements represent an important step forward for Dyne as we pursue our mission of delivering life-transforming therapies for serious muscle diseases,” said Joshua Brumm, president and chief executive officer of Dyne. “Jeff brings comprehensive insights into FSHD, including cutting-edge research into molecular and neuroimaging biomarkers that may be useful in assessing disease progression in future clinical trials. The agreement with UMONS gives us exclusive access to intellectual property to target the genetic cause of FSHD and complements our own proprietary platform for precision delivery into muscle cells.” “There is a critical need for therapies to treat FSHD, which takes a debilitating physical and emotional toll on affected individuals and families,” said Dr. Statland. “The Dyne team is advancing FSHD research with their support of the ReSolve study and I believe their FORCE platform holds great potential. I am delighted to join Dyne’s Scientific Advisory Board.” Dr. Statland is an associate professor of neurology at the University of Kansas Medical Center, with both clinical and research training in neuromuscular diseases. His primary research interest is in FSHD. In addition to co-leading the ReSolve Natural History Study, Dr. Statland, with his collaborators at the University of Rochester Medical Center, is developing a disease-specific patient-reported health inventory and molecular and neuroimaging biomarkers of disease activity for future FSHD clinical trials. Dr. Statland holds a B.A. from Sarah Lawrence College, an MFA from Emerson College and an M.D. from the University of Kansas School of Medicine. He completed residency training in the Department of Neurology at the University of Kansas Medical Center and also conducted a fellowship in experimental therapeutics of neurologic disorders in the Department of Neurology at the University of Rochester Medical Center. He is board certified by the American Board of Psychiatry and Neurology. About Dyne Therapeutics Dyne Therapeutics is pioneering life-transforming therapies for patients with serious muscle diseases. The company’s FORCETM platform delivers oligonucleotides and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision to restore muscle health. Dyne is advancing treatments for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Dyne was founded by Atlas Venture and is headquartered in Waltham, Mass. For more information, please visit www.dyne-tx.com, and follow us on TwitterLinkedIn and Facebook. Media Contact Ten Bridge Communications Stephanie Simon, (617) 581-9333 stephanie@tenbridgecommunications.com Enhanced dystrophin expression in multiple muscle tissues and sustained functional benefit in DMD disease model following single low dose Data presented at American Society of Gene & Cell Therapy Annual Meeting WALTHAM, Mass. – Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced data demonstrating enhanced dystrophin expression in multiple muscle tissues and significant improvement in muscle function in a preclinical model of Duchenne muscular dystrophy (DMD) following treatment with the company’s FORCE™ platform. The findings were highlighted in a poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting. “Targeting therapeutics directly to muscle tissue has been an enormous challenge for the industry for years. These exciting data reinforce our confidence that Dyne’s FORCE platform can overcome this challenge and effectively deliver transformational therapies for DMD and other serious muscle diseases,” said Joshua Brumm, president and CEO of Dyne. “We are focused on advancing our programs to the clinic, where we believe they will translate into life-changing benefits for patients.” Dyne’s FORCE platform targets the TFR-1 receptor, which is highly expressed on the surface of muscle cells, enabling targeted delivery of a disease-modifying therapeutic payload directly to skeletal, cardiac and smooth muscle tissue. In DMD, the FORCE platform delivers exon-skipping antisense oligonucleotides to muscle cells to enable expression of a more complete, functional dystrophin protein and halt the severe muscle degeneration that characterizes DMD. Key findings presented at ASGCT include: “We’re excited to showcase the power of the FORCE platform to deliver redosable, titratable and highly targeted exon-skipping therapies,” said Romesh Subramanian, Ph.D., Dyne’s chief scientific officer. “ASO uptake across muscle tissue types — including the quadriceps, diaphragm and heart — is far more robust with the FORCE platform. Importantly, we have shown that this uptake results in both increased dystrophin expression and clear functional benefits in a validated DMD disease model. Those benefits were observed following a single low dose and sustained for at least a month post-treatment.” Along with DMD, Dyne is advancing programs in myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD). The ASGCT poster, “Targeted Delivery of ASOs Demonstrates Potential to Treat Duchenne Muscular Dystrophy,” is available for virtual viewing here. About Dyne Therapeutics Dyne Therapeutics is pioneering life-transforming therapies for patients with serious muscle diseases. The company’s FORCE™ platform delivers oligonucleotides and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision to restore muscle health. Dyne is advancing treatments for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Dyne was founded by Atlas Venture and is headquartered in Waltham, Mass. For more information, please visit www.dyne-tx.com, and follow us on Twitter and LinkedIn. Media Contact Ten Bridge Communications Stephanie Simon, (617) 581-9333 stephanie@tenbridgecommunications.com Ms. Feldman is an experienced regulatory affairs leader with expertise in rare and neuromuscular disease  WALTHAM, Mass. – Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced the appointment of Debra Feldman as vice president, head of regulatory. Ms. Feldman most recently served as vice president, regulatory affairs at Sage Therapeutics, and brings over 20 years of experience managing regulatory initiatives. “People with serious muscle diseases and their families urgently need therapies with the potential to address the disease burden they face,” said Ms. Feldman. “I am thrilled to be joining Dyne at a pivotal time in our development, as we advance rapidly toward the clinic.” “Debra brings significant experience in global regulatory strategy to the Dyne team, including substantial knowledge of the rare disease and neuromuscular spaces,” said Joshua Brumm, president and chief executive officer of Dyne. “Her expertise in navigating regulatory pathways will be invaluable as we rapidly progress our programs toward clinical development, with the aim of developing life-saving therapies for serious muscle diseases.” Ms. Feldman is an accomplished R&D leader with more than 20 years of regulatory experience in biotech and the life sciences. She has reviewed and authored numerous successful INDs, CTAs, NDAs, MAAs and submissions for breakthrough, fast track, orphan drug and pediatric designations to advance innovative and data-driven science. Prior to joining Dyne, Ms. Feldman led the regulatory organization at Sage Therapeutics, overseeing regulatory initiatives across a pipeline of products to address neurological and psychiatric disorders. During her time at Sage, she led the company through the approval of ZULRESSO® (brexanolone), the first and only treatment specifically indicated for postpartum depression. Prior to Sage, Ms. Feldman held various regulatory roles focused on multiple therapeutic areas, including rare diseases. She holds a B.A. from University of Massachusetts, Amherst, a degree in nutritional science from Simmons College and a Master of Public Health from Boston University. About Dyne Therapeutics Dyne Therapeutics is pioneering life-transforming therapies for patients with serious muscle diseases. The company’s FORCE™ platform delivers oligonucleotides and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision to restore muscle health. Dyne is advancing treatments for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Dyne was founded by Atlas Venture and is headquartered in Waltham, Mass. For more information, please visit www.dyne-tx.com, and follow us on Twitter and LinkedIn. Media Contact Ten Bridge Communications Stephanie Simon, (617) 581-9333 stephanie@tenbridgecommunications.com Lubner brings 25 years of financial and operational experience in the life sciences industry WALTHAM, Mass. – Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced the appointment of David Lubner, a senior finance executive with more than 25 years of experience in the life sciences industry, to Dyne’s Board of Directors. “We are pleased to welcome David to the Board. He is a seasoned life sciences leader with experience spanning strategy, finance, capital markets, M&A and operations including a strong track record in rare disease,” said Jason P. Rhodes, executive chairman of Dyne’s Board of Directors and partner at Atlas Venture. “I am excited to join Dyne as the company develops therapeutics for patients with myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and other serious muscle diseases based on their pioneering FORCE™ platform,” said Lubner. “I look forward to working closely with the Board and leadership team to execute our growth and capital strategies.” “On behalf of Dyne’s team, I am thrilled to welcome David to the Board,” said Joshua Brumm, president and chief executive officer of Dyne. “We look forward to his contributions as we build the leading muscle disease company and rapidly advance our programs toward the clinic.” Lubner serves as executive vice president and chief financial officer of Ra Pharma, acquired by UCB in April 2020. Before joining Ra Pharma, he served as a member of the senior management team of Tetraphase Pharmaceuticals, Inc. and PharMetrics Inc., a leading patient-based pharmacy and medical claims data informatics company, and at ProScript, where Velcade® (bortezomib), a therapy widely used for treatment of the blood cancer multiple myeloma, was discovered. In addition to Dyne’s Board of Directors, he previously served on the Board of Directors of Nightstar Therapeutics plc (Nasdaq: NITE), a company focused on the development of one-time retinal gene therapies for patients suffering from rare inherited retinal diseases, which was acquired by Biogen in June 2019. Lubner is a Certified Public Accountant. He received his B.S. in business administration from Northeastern University and an M.S. in taxation from Bentley University. About Dyne Therapeutics Dyne Therapeutics is pioneering life-transforming therapies for patients with serious muscle diseases. The company’s FORCE™ platform delivers oligonucleotides and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision to restore muscle health. Dyne is advancing treatments for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Dyne was founded by Atlas Venture and is headquartered in Waltham, Mass. For more information, please visit www.dyne-tx.com, and follow us on Twitter and LinkedIn. Media Contact  Ten Bridge Communications Stephanie Simon, (617) 581-9333 stephanie@tenbridgecommunications.com WALTHAM, Mass. –­­­ Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced an equity investment from CureDuchenne Ventures. The funding will support Dyne’s development of precision therapeutics designed to restore muscle health in people living with Duchenne muscular dystrophy (DMD). “Dyne’s partnership with CureDuchenne underscores our deep commitment and our sense of urgency as we work to bring life-transforming therapies to patients living with DMD and other serious muscle disorders. We appreciate the collaboration with and investment from CureDuchenne Ventures, which will help us advance our novel approach to targeting the genetic basis of DMD, with the goal of halting disease progression and restoring muscle health,” said Joshua Brumm, Dyne’s president and chief executive officer. “We look forward to continuing to collaborate with CureDuchenne and all of our partners in the Duchenne community. Together, we will improve the lives of those impacted by this devastating disease.” Dyne’s FORCE™ platform enhances the delivery of exon skipping therapeutics to skeletal, cardiac and smooth muscle with the potential to improve efficacy and reduce dosing frequency. The company’s DMD therapeutic molecule consists of an antibody linked to an exon skipping oligonucleotide. The antibody binds to specific receptors that are highly expressed on the surface of muscle cells. Once a receptor is engaged, the antibody delivers the exon skipping oligonucleotide inside the cell, enhancing mRNA modification in the nucleus and increasing dystrophin production. This approach is designed to promote muscle health and stop the progressive loss of muscle function that characterizes DMD. “CureDuchenne Ventures is delighted to support Dyne as part of our comprehensive approach to finding a cure for Duchenne, and we remain committed to bringing meaningful therapeutic advances to every person living with Duchenne,” said Debra Miller, founder and CEO of CureDuchenne. “We are excited about the progress of Dyne’s Duchenne program and the opportunity to rapidly advance to clinical studies. We know that progress comes from approaching research from multiple angles, and believe that Dyne’s FORCE platform holds substantial promise for advancing precision exon skipping therapies that are targeted to reach affected muscles throughout the body.” About Dyne Therapeutics Dyne Therapeutics is pioneering life-transforming therapies for patients with serious muscle diseases. The company’s FORCE™ platform delivers oligonucleotides and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision to restore muscle health. Dyne is advancing treatments for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Dyne was founded by Atlas Venture and is headquartered in Waltham, Mass. For more information, please visit dyne-tx.com, and follow us on Twitter and LinkedIn. About CureDuchenne CureDuchenne is recognized as a global leader in research, patient care and innovation for improving and extending the lives of those with Duchenne muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 individuals living today. CureDuchenne is dedicated to finding and funding a cure for Duchenne by breaking the traditional charitable mold through an innovative venture philanthropy model that funds groundbreaking research, early diagnosis and community education. For more information on how to help raise awareness and funds needed for research, please visit www.cureduchenne.org. For more details about CureDuchenne’s philanthropic investments, go to: https://www.cureduchenne.org/ventures/ Media Contact Ten Bridge Communications Stephanie Simon, (617) 581-9333 stephanie@tenbridgecommunications.com Former chief executive officer of Myotonic brings extensive experience in patient advocacy and community engagement WALTHAM, Mass.– Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced the appointment of Molly White as Vice President, Medical Communications and Advocacy. Ms. White previously served as chief executive officer of Myotonic (formerly the Myotonic Dystrophy Foundation), the world’s largest patient organization focused solely on myotonic dystrophy. “We have a unique opportunity at Dyne to fundamentally change the course of serious muscle diseases and their impact on families and caregivers around the world,” said Ms. White. “I’m excited to join the dedicated team at Dyne and to support the advancement of our potentially transformative lead program in myotonic dystrophy type 1 (DM1), as well as our programs in Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD), through meaningful engagement with the patient and scientific communities.” “We’re thrilled to begin the year by adding Molly to our rapidly growing team at Dyne,” said Joshua Brumm, president and chief executive officer of Dyne. “With her experience leading Myotonic, Molly has demonstrated outstanding leadership and passionate advocacy in seeking to change the lives of those affected by myotonic dystrophy. We look forward to her contributions as we continue to build the leading muscle disease company and deliver on our sincere commitment to patients.” Prior to joining Dyne, Ms. White served as chief executive officer of Myotonic, an organization dedicated to advancing research and enhancing the quality of life of people living with myotonic dystrophy. In that role, she led strategic direction and administrative oversight for the comprehensive programmatic and fundraising efforts of the foundation and its staff. Ms. White has over 25 years of leadership-level experience building, implementing and running award-winning domestic and international community programs for organizations in both the private and nonprofit sectors. She has created partnerships with a range of governmental, nonprofit and private sector stakeholders to launch initiatives targeting key national issues such as childhood obesity prevention and components of healthcare reform. Ms. White holds a B.A. from the University of Montana and an M.A. from the University of Iowa. She has received certification from the Center for Corporate Community Relations, Boston University and from the Fund Raising School, Center on Philanthropy, Indiana University. She has also served as a board member for numerous community organizations. About Dyne Therapeutics Dyne Therapeutics is pioneering life-transforming therapies for patients with serious muscle diseases. The company’s FORCE™ platform delivers oligonucleotides and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision to restore muscle health. Dyne is advancing treatments for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). Dyne was founded in 2018 and is based in Waltham, Mass. For more information, please visit www.dyne-tx.com. Media Contact Ten Bridge Communications Max Stendahl, 508-277-8117 max@tenbridgecommunications.com